In this context, LHRH agonist treatment by suppressing effective ovarian function may lead to a hypoestrogenic status that may positively impact breast cancer prognosis (23) and prevent the effects of tamoxifen at the gynecological level (endometrial hyperplasia and ovarian cyst formation) (26). Here, GNRH1 is linked to breast cancer.